Raw Material Overview

Streptococcus salivarius G7 + Lactiplantibacillus plantarum GSPE05
G7 Mixed Probiotics Powder
Patented probiotics for simultaneous oral and respiratory health
  • Mixed probiotics comprising Streptococcus salivarius G7 isolated from the gingiva of healthy Korean adult males and Lactiplantibacillus plantarum GSPE05 isolated from Korean Naju pears
  • Patented Streptococcus salivarius G7 strain specialized for oral health and patented Lactiplantibacillus plantarum GSPE05 specialized for respiratory health
  • Superior antibacterial efficacy through synergistic effects of the two-strain combination
  • Patent filed for the antifungal activity of Lactiplantibacillus plantarum GSPE05
  • Both strains deposited (Korean Culture Center of Microorganisms, Korea Research Institute of Bioscience and Biotechnology)
  • Safety assessment completed according to MFDS guidelines
Material Name G7 Mixed Probiotics Powder
Recommended Daily Intake 2 billion CFU/day
Recommended Intake Duration 4 weeks
Experimental Results
  • Test Material

    Streptococcus salivarius G7
    +
    Lactiplantibacillus plantarum GSPE05

Excellent antibacterial efficacy against cavity-causing bacteria (mutans bacteria) and gingivitis-causing bacteria (gingivalis bacteria), Excellent antibacterial efficacy against respiratory disease-causing bacteria (Moraxella catarrhalis bacteria) and excellent synergistic effects when two strains are combined
Experimental Results
  • Investigational product (IP)

    Lactiplantibacillus plantarum GSPE05

  • Respiratory health

    01.Inhibition of upper respiratory pathogens.

    02.Strong adhesion to bronchial epithelial cells.

    1) Korean Patent No. 10-2692457
  • Anti-inflammatory effect

    01.Reduction of asthma-induced allergic inflammation.

    02.Reduces allergies and inflammatory responses

    1) Korean Patent No. 10-2692457
  • Oral health

    01.Antifungal activity against stomatitis pathogens.

    02.Inhibitory effect against antifungal-resistant fungi.

01
Respiratory health
Inhibition of pathogens causing
upper respiratory tract infections.

Antibacterial activity against upper respiratory pathogens (5 strains).

Bronchial-adherent
probiotics

Strong adhesion to human bronchial epithelial cells.

02
Anti-inflammatory effect

Reduction of asthma-induced allergic inflammation.

L. plantarum GSPE05 attenuates allergic inflammatory responses, such as asthma, by inhibiting β-hexosaminidase release from mast cells and suppressing the secretion of inflammatory mediators induced by allergic antigens.

Reduces allergies and inflammatory responses

03
Oral health

Antifungal effect on stomatitis pathogens (C. albicans).

Efficacy against antifungal-resistant fungi.

L. plantarum GSPE05 produces potent antifungal substances that effectively inhibit not only common C. albicans but also antifungal-resistant strains.

Patents
  • Korea Registration
    Patent No. 10-2796381

    Antibacterial composition against pathogenic bacteria comprising Streptococcus salivarius G7 and Lactobacillus plantarum GSPE05 culture

  • Korea Registration
    Patent No. 10-2848348

    Antibacterial composition against pathogenic bacteria comprising Streptococcus salivarius G7 and Lactobacillus plantarum GSPE05 culture

  • Korea Registration
    Patent No. 10-2692457

    Lactobacillus plantarum GSPE05 and uses thereof

  • Korea Registration